Literature DB >> 16697355

Chronic treatment with mood stabilizers increases membrane GRK3 in rat frontal cortex.

Renee N Ertley1, Richard P Bazinet, Ho-Joo Lee, Stanley I Rapoport, Jagadeesh S Rao.   

Abstract

BACKGROUND: G-protein receptor kinases (GRKs) are a family of serine/threonine kinases involved in the homologous desensitization of agonist activated G-protein coupled receptors (GPCRs). G-protein coupled receptor supersensitivity, possibly as a result of decreased GRK, has been suggested in affective disorders.
METHODS: We used immunobloting to determine if chronic, therapeutically relevant doses of lithium (Li+), carbamazepine (CBZ), and valproate (VPA), would increase GRK2/3 protein levels in rat frontal cortex.
RESULTS: Chronic Li+ (24%) and CBZ (44%) significantly increased GRK3 in the membrane but not cytosol fractions. Chronic VPA had no effect on GRK3. G-protein receptor kinase 2 protein levels were unchanged by all treatments. The GRK3 membrane to cytosol ratio was increased significantly in Li+ and CBZ treated rats.
CONCLUSIONS: These results show that chronically administered Li+ and CBZ, but not VPA, increase the translocation of GRK3 from cytosol to membrane, possibly correcting supersensitivity of GPCRs in bipolar disorder.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16697355     DOI: 10.1016/j.biopsych.2006.03.022

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  9 in total

1.  Increased G protein-coupled receptor kinase (GRK) expression in the anterior cingulate cortex in schizophrenia.

Authors:  Adam J Funk; Vahram Haroutunian; James H Meador-Woodruff; Robert E McCullumsmith
Journal:  Schizophr Res       Date:  2014-08-19       Impact factor: 4.939

Review 2.  Lithium and the other mood stabilizers effective in bipolar disorder target the rat brain arachidonic acid cascade.

Authors:  Stanley I Rapoport
Journal:  ACS Chem Neurosci       Date:  2014-05-15       Impact factor: 4.418

3.  Differential effects of inescapable stress on locus coeruleus GRK3, alpha2-adrenoceptor and CRF1 receptor levels in learned helpless and non-helpless rats: a potential link to stress resilience.

Authors:  Manish Taneja; Samina Salim; Kaustuv Saha; H Kevin Happe; Nidal Qutna; Frederick Petty; David B Bylund; Douglas C Eikenburg
Journal:  Behav Brain Res       Date:  2011-02-17       Impact factor: 3.332

Review 4.  Second messenger/signal transduction pathways in major mood disorders: moving from membrane to mechanism of action, part II: bipolar disorder.

Authors:  Mark J Niciu; Dawn F Ionescu; Daniel C Mathews; Erica M Richards; Carlos A Zarate
Journal:  CNS Spectr       Date:  2013-03-11       Impact factor: 3.790

5.  Allele specific analysis of the ADRBK2 gene in lymphoblastoid cells from bipolar disorder patients.

Authors:  Michael J McCarthy; Thomas B Barrett; Stephanie Nissen; John R Kelsoe; Eric E Turner
Journal:  J Psychiatr Res       Date:  2009-09-18       Impact factor: 4.791

6.  Decreased GRK3 but not GRK2 expression in frontal cortex from bipolar disorder patients.

Authors:  Jagadeesh S Rao; Stanley I Rapoport; Hyung-Wook Kim
Journal:  Int J Neuropsychopharmacol       Date:  2009-04-29       Impact factor: 5.176

7.  Chronic carbamazepine administration attenuates dopamine D2-like receptor-initiated signaling via arachidonic acid in rat brain.

Authors:  Mireille Basselin; Lisa Chang; Mei Chen; Jane M Bell; Stanley I Rapoport
Journal:  Neurochem Res       Date:  2008-02-27       Impact factor: 3.996

Review 8.  Bipolar disorder and mechanisms of action of mood stabilizers.

Authors:  Stanley I Rapoport; Mireille Basselin; Hyung-Wook Kim; Jagadeesh S Rao
Journal:  Brain Res Rev       Date:  2009-06-23

9.  Neuropathological responses to chronic NMDA in rats are worsened by dietary n-3 PUFA deprivation but are not ameliorated by fish oil supplementation.

Authors:  Vasken L Keleshian; Matthew Kellom; Hyung-Wook Kim; Ameer Y Taha; Yewon Cheon; Miki Igarashi; Stanley I Rapoport; Jagadeesh S Rao
Journal:  PLoS One       Date:  2014-05-05       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.